促性腺激素释放激素激动剂与米非司酮治疗子宫肌瘤的临床疗效
|
摘要
目的探讨促性腺激素释放激素激动剂(Gn RH-a)与米非司酮治疗子宫肌瘤患者的临床效果。方法选取2016年1—12月营口市鲅鱼圈区妇幼保健计划生育服务中心收治的子宫肌瘤患者84例作为研究对象,随机分为两组,A组(GnRH-a组)与B组(米非司酮组),各42例,比较两组患者的治疗效果。结果治疗后两组子宫体积、子宫肌瘤均有所缩小,且B组子宫体积、子宫肌瘤均明显小于A组,差异有统计学意义(P<0.05);治疗后两组月经量增多、下腹坠痛、尿频、痛经患者比例明显下降,且B组月经量增多、痛经患者比例明显低于A组,差异有统计学意义(P<0.05)。结论与GnRH-a相比较,米非司酮治疗子宫肌瘤的临床疗效更好。
Objective To explore the clinical efficacy of gonadotropin releasing hormone agonist(GnRH-a) and mifepristone in the treatment of uterine leiomyoma. Methods A total of 84 patients with uterine leiomyoma admitted to the Maternal and Child Health and Family Planning Service Center of Yingkou Bayuquan Zone from January to December 2016 were selected as research objects, and randomly divided into 2 groups, group A(GnRH-a group) and group B(mifepristone group), with 42 cases in each group. The therapeutic effects of the 2 groups were compared. Results After the treatment, uterine volume and uterine leiomyoma in both groups were reduced, and the uterine volume and uterine leiomyoma in the group B were significantly smaller than those in the group A, and the difference was statistically significant(P<0.05); after the treatment, the patient proportions of increased menstrual volume, lower abdominal bearing-down pain, frequent urination and dysmenorrhea in both groups were significantly decreased, and the patient proportions of increased menstrual volume and dysmenorrhea in the group B were significantly lower than those in the group A, and the difference was statistically significant(P<0.05). Conclusion Compared with GnRH-a, mifepristone has better clinical efficacy in the treatment of uterine leiomyoma.
Objective To explore the clinical efficacy of gonadotropin releasing hormone agonist(GnRH-a) and mifepristone in the treatment of uterine leiomyoma. Methods A total of 84 patients with uterine leiomyoma admitted to the Maternal and Child Health and Family Planning Service Center of Yingkou Bayuquan Zone from January to December 2016 were selected as research objects, and randomly divided into 2 groups, group A(GnRH-a group) and group B(mifepristone group), with 42 cases in each group. The therapeutic effects of the 2 groups were compared. Results After the treatment, uterine volume and uterine leiomyoma in both groups were reduced, and the uterine volume and uterine leiomyoma in the group B were significantly smaller than those in the group A, and the difference was statistically significant(P<0.05); after the treatment, the patient proportions of increased menstrual volume, lower abdominal bearing-down pain, frequent urination and dysmenorrhea in both groups were significantly decreased, and the patient proportions of increased menstrual volume and dysmenorrhea in the group B were significantly lower than those in the group A, and the difference was statistically significant(P<0.05). Conclusion Compared with GnRH-a, mifepristone has better clinical efficacy in the treatment of uterine leiomyoma.
引文
[1]郑真真,孙静.子宫肌瘤的治疗进展[J].海南医学,2014,25(3):383-386.
[2]李传菊.80例子宫肌瘤药物治疗的临床分析[J].中国医学创新,2011,8(6):52-53.
[3]张慧英.子宫肌瘤药物治疗进展[J].国际妇产科学杂志,2013,40(4):339-342.
[4]冯金辉,陈丽萍,支霜,等.米非司酮治疗子宫肌瘤的临床观察[J].中国性科学,2013,22(5):27-29,42.
[5]聂惠龙,郭天棋,张琳,等.不同剂量米非司酮治疗子宫肌瘤的临床效果观察[J].中国妇幼保健,2016,31(22):4683-4684.
[6]潘振球,范丽英,金亚蓓.不同剂量米非司酮治疗围绝经期子宫肌瘤诱导绝经的临床效果观察[J].中国生化药物杂志,2015,35(12):79-80,83.
[7]冷如冰.米非司酮治疗子宫肌瘤的临床效果观察100例[J].中国社区医师,2016,32(1):49-50.
[8]梁旭.四君子汤合桂枝茯苓丸加减治疗子宫肌瘤临床研究[J].亚太传统医药,2016,12(6):145-146.
[9]陈素芬.米非司酮联合宫瘤消治疗子宫肌瘤临床观察[J].中医学报,2014,29(7):79.
[10]黄起.小剂量米非司酮治疗子宫肌瘤90例临床观察[J].临床和实验医学杂志,2010,9(12):931-932.
[11]Ebell MH.Mifepristone Pretreatment Improves Success Rate of Misoprostol for Early Pregnancy Loss[J].Am Fam Physician,2018,98(11):683-684.
[2]李传菊.80例子宫肌瘤药物治疗的临床分析[J].中国医学创新,2011,8(6):52-53.
[3]张慧英.子宫肌瘤药物治疗进展[J].国际妇产科学杂志,2013,40(4):339-342.
[4]冯金辉,陈丽萍,支霜,等.米非司酮治疗子宫肌瘤的临床观察[J].中国性科学,2013,22(5):27-29,42.
[5]聂惠龙,郭天棋,张琳,等.不同剂量米非司酮治疗子宫肌瘤的临床效果观察[J].中国妇幼保健,2016,31(22):4683-4684.
[6]潘振球,范丽英,金亚蓓.不同剂量米非司酮治疗围绝经期子宫肌瘤诱导绝经的临床效果观察[J].中国生化药物杂志,2015,35(12):79-80,83.
[7]冷如冰.米非司酮治疗子宫肌瘤的临床效果观察100例[J].中国社区医师,2016,32(1):49-50.
[8]梁旭.四君子汤合桂枝茯苓丸加减治疗子宫肌瘤临床研究[J].亚太传统医药,2016,12(6):145-146.
[9]陈素芬.米非司酮联合宫瘤消治疗子宫肌瘤临床观察[J].中医学报,2014,29(7):79.
[10]黄起.小剂量米非司酮治疗子宫肌瘤90例临床观察[J].临床和实验医学杂志,2010,9(12):931-932.
[11]Ebell MH.Mifepristone Pretreatment Improves Success Rate of Misoprostol for Early Pregnancy Loss[J].Am Fam Physician,2018,98(11):683-684.